Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma

Kite, a Gilead Company (Nasdaq: GILD), and Teneobio, Inc. announced the companies have entered into a license and collaboration agreement through which Kite will receive exclusive rights to certain antibodies directed to B-cell maturation antigen (BCMA).